ACC 2017: Double-Whammy Trial Data Boost For Philips' iFR
Results from the iFR SWEDEHEART and DEFINE-FLAIR trials, both presented at this month's American College of Cardiology Scientific Sessions in Washington, DC, show that coronary revascularization guided by instantaneous wave-free ratio measurement is non-inferior to fractional flow reserve measurement in guiding coronary revascularization
You may also be interested in...
The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.
The EuroPCR conference in Paris is the most important annual interventional cardiology conference in Europe and this year's edition brought more data from clinical trials of both established catheter-based technologies and innovative new devices.
Imaging giant Philips is hoping acquisitions will help it out of its current slump, betting €800m ($1bn) on cardiovascular device specialist Volcano. The deal is worth $18 per Volcano share, a 57% premium over its closing price of $11.49 on 16 December, the day the acquisition was announced.